London, Jun 15 (EFE).- British-Swedish pharmaceutical AstraZeneca on Tuesday said a study of its monoclonal antibody treatment did not meet its desired objective in preventing symptomatic Covid-19 after exposure.
In a statement, AstraZeneca said those who participated in the trial were above the age of 18 and had not been vaccinated, with a confirmed exposure to a person with the virus within the past eight days.
The antibody combination called AZD7442 “reduced the risk of developing symptomatic Covid-19 by 33% compared to placebo, which was not statistically significant,” the pharmaceutical company said.
Myron Levin, a pediatric professor, stressed the need for treatment options for those “unable to be vaccinated or those who may have an inadequate response to vaccination (against coronavirus).”
Monoclonal antibody treatment belongs to a group of drugs stimulating natural antibodies the body produces to fight infection. EFE